tradingkey.logo

Abbvie And Remegen Announce Exclusive Licensing Agreement To Develop A Novel Bispecific Antibody For Advanced Solid Tumors

ReutersJan 12, 2026 12:36 PM

- RemeGen Co Ltd 688331.SS:

  • ABBVIE AND REMEGEN ANNOUNCE EXCLUSIVE LICENSING AGREEMENT TO DEVELOP A NOVEL BISPECIFIC ANTIBODY FOR ADVANCED SOLID TUMORS

  • ABBVIE: REMEGEN ELIGIBLE TO RECEIVE UP TO USD $4.95 BILLION IN AGGREGATE DEVELOPMENT, REGULATORY, AND COMMERCIAL MILESTONE PAYMENTS

  • ABBVIE: REMEGEN WILL RECEIVE AN UPFRONT PAYMENT OF UPTO $650 MILLION

  • ABBVIE: WILL RECEIVE EXCLUSIVE RIGHTS TO DEVELOP, MANUFACTURE, AND COMMERCIALIZE RC148 OUTSIDE OF GREATER CHINA TERRITORY

  • ABBVIE: REMEGEN WILL RECEIVE AN UPFRONT PAYMENT OF USD $650 MILLION

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI